Dr. Schiff (IMAGE)
Caption
“We found that the 10-year survival rate was 70% with the combined treatment with temozolomide chemotherapy and radiation, compared to 47% with radiation alone as the initial approach. This discovery is important because until now, we have not had compelling evidence that temozolomide improves overall survival in grade 2 gliomas,” said lead investigator David Schiff, MD, the Harrison Distinguished Professor of Neurology, Neurological Surgery and Medicine and co-director of the UVA Neuro-Oncology Center at the University of Virginia.
Credit
University of Virginia
Usage Restrictions
No restrictions.
License
Public Domain